Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Russell 2000 ETF (NY:IWM)

246.02 -4.03 (-1.61%)
Official Closing Price Updated: 4:10 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 ETF

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Market Breadth Analysis – Relief Rally Continues, But Internal Damage Is Still Visible ↗
Via Chartmill
Market Breadth Rebounds Sharply, But the Broader Damage Is Still Visible ↗
Via Chartmill
News headline image
IWM vs. IJR: Two Small-Cap ETFs That Look Very Different ↗
Small-cap investing is finally back in favor again. But you need to examine these ETFs closely to know exactly what you're buying. 
Via The Motley Fool
Topics ETFs
News headline image
SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline ↗
Energy Secretary Chris Wright issued the order to Sable on March 13, directing it to immediately prioritize and allocate pipeline transportation services for hydrocarbons between the two units. 
Via Stocktwits
Market Breadth Remains Weak as Selling Pressure Stays Broad ↗
Via Chartmill
News headline image
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval. 
Via Stocktwits
Topics Earnings
Weak Breadth Deepens as Support Levels Come Under Pressure ↗
Via Chartmill
Market Breadth Deteriorates Further as Participation Keeps Narrowing ↗
Via Chartmill
Market Breadth Deteriorates Again as Tuesday’s Rebound Attempt Fades ↗
Via Chartmill
News headline image
Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance ↗
Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. 
Via Stocktwits
Topics Retirement
News headline image
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy ↗
For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024. 
Via Stocktwits
News headline image
The Concentration Cliff: Market Breadth Narratives Shift as Records Mask Underlying Rot
As of March 12, 2026, the U.S. stock market presents a jarring paradox that has left seasoned analysts sounding the alarm. While the flagship S&P 500 (NYSE: SPY) recently flirted with the historic... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Market Breadth Rebounds, But Internal Damage Still Runs Deep ↗
Via Chartmill
Market Breadth Turns More Defensive as Selling Pressure Broadens ↗
Via Chartmill
Breadth Breaks Down Again as the Bounce Fails ↗
Via Chartmill
News headline image
DigiMarc Stock Rallies After Hours On Q4 Revenue Beat ↗
DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. 
Via Stocktwits
Topics Intellectual Property
News headline image
Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run? ↗
The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 
Via Stocktwits
News headline image
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study ↗
The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 
Via Stocktwits
Topics Death
News headline image
Sable Offshore To Reportedly Get Trump Support Via Emergency Law To Restart Production ↗
A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report. 
Via Stocktwits
Topics Government
News headline image
Domo Posted A Double Beat On Q4 Results — So Why Is The Street Slashing Targets? ↗
The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait ↗
The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16. 
Via Stocktwits
News headline image
Groupon Stock Fell 11% After Hours – Here’s Why ↗
The company said its revenue was $132.7 million in the fourth quarter 2025, below analyst expectations of $136.7 million, as per data from Fiscal.ai. 
Via Stocktwits
News headline image
CRML Shares Breach $10 Mark On Rare Earth Project Acceleration In Greenland — How Much More Upside Does The Street See? ↗
Freedom Capital initiated coverage of Critical Metals with a ‘Buy’ rating and $15 price target, representing an upside of almost 50% from its current price levels. 
Via Stocktwits
News headline image
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
Via Stocktwits
Topics Intellectual Property
News headline image
ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment ↗
For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million. 
Via Stocktwits
News headline image
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗
The company announced its decision following a meeting with the U.S. Food and Drug Administration. 
Via Stocktwits
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease. 
Via Stocktwits
News headline image
Small-Caps Shine as "Magnificent Seven" Lose Luster in 2026 Market Pivot
In the first quarter of 2026, the financial markets have undergone a definitive "regime change" that many analysts are calling the "Great Convergence." After years of an increasingly narrow market led... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Newsmax Stock Heads For Best Week Since IPO Amid Spate Of Trump News; Retail Traders See Short Squeeze Coming ↗
The sharp rally has piqued retail traders’ interest in the conservative-leaning news network. 
Via Stocktwits
Topics Government Initial Public Offering
News headline image
Webull Stock Continues Decline After Q4 Earnings Miss – What Does The Street Think? ↗
Rosenblatt lowered the firm's price target on Webull to $12 from $15 and kept a ‘Buy’ rating on the shares, per TheFly. 
Via Stocktwits
Topics Bonds Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.